TY - JOUR
T1 - Costs and health effects of CT perfusion-based selection for endovascular thrombectomy within 6 hours of stroke onset
T2 - a model-based health economic evaluation
AU - Van Voorst, Henk
AU - Hoving, Jan W.
AU - Koopman, Miou S.
AU - Daems, Jasper D.
AU - Peerlings, Daan
AU - Buskens, Erik
AU - Lingsma, Hester
AU - Marquering, Henk A.
AU - De Jong, Hugo W.A.M.
AU - Berkhemer, Olvert A.
AU - Van Zwam, Wim H.
AU - Van Walderveen, Marianne A.A.
AU - Van Den Wijngaard, Ido R.
AU - Dippel, Diederik W.J.
AU - Yoo, Albert J.
AU - Campbell, Bruce
AU - Kunz, Wolfgang G.
AU - Majoie, Charles B.
AU - Emmer, Bart J.
AU - Staals, Julie
AU - de Ridder, Inger
AU - van Oostenbrugge, Robert Jan
AU - Postma - Jacobi, Linda
AU - van der Leij, Christiaan
AU - Brans, Rutger
AU - Pirson, Anne-France
AU - Olthuis, Susanne
AU - Pinckaers, Floor
AU - Hinsenveld, Wouter
AU - Goldhoorn, Robert-Jan
AU - Truijman, Martine
AU - ten Cate, Hugo
AU - CLEOPATRA Investigators
AU - MR CLEAN Registry Investigators
N1 - Funding Information:
BJE reports grants from LtC (ZonMW and TKI-PPP of Health Holland). WHvZ reports speaker fees from Cerenovus, NicoLab and Stryker, and consulting fees from Philips, all paid to Institution. DWJD report grants from the Dutch Heart Foundation, Brain Foundation Netherlands, ZON MW, Stryker, Medtronic, Cerenovus, Thrombolytic Science, received by the Erasmus University Medical Center outside this project. AJY reports Research grants from Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. Consultant for Penumbra, Cerenovus, Nicolab, Philips, Vesalio, Zoll Circulation, and NIH/NINDS. CBM: grants from Healthcare Evaluation Netherlands, CVON/Dutch Heart Foundation, TWIN foundation and Stryker during the conduct of the study and from European Commission outside this project (all paid to institution) and is shareholder of Nicolab. All other contributors report no other conflicts of interest.
Funding Information:
The CLEOPATRA healthcare evaluation study was funded by Leading the Change (LtC). LtC is financed by Zorgverzekeraars Nederland (ZN) and supports various healthcare evaluations in the Netherlands as part of the ‘Healthcare Evaluation Netherlands’ project. LtC was not involved in the study design, monitoring, data collection, statistical analyses, interpretation of results or manuscript writing, but the progress of the study was continuously monitored by LtC. The MR CLEAN-NO IV trial ( ISRCTN80619088 ) and MR CLEAN-MED trial ( ISRCTN76741621 ) were part of the Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium. The CONTRAST consortium acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01: CONTRAST), and from the Brain Foundation Netherlands (HA2015.01.06). The collaboration project is additionally financed by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (LSHM17016). This work was funded in part through unrestricted funding by Stryker, Medtronic and Cerenovus. The funding sources were not involved in study design, monitoring, data collection, statistical analyses, interpretation of results or manuscript writing.
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Background Although CT perfusion (CTP) is often incorporated in acute stroke workflows, it remains largely unclear what the associated costs and health implications are in the long run of CTP-based patient selection for endovascular treatment (EVT) in patients presenting within 6 hours after symptom onset with a large vessel occlusion. Methods Patients with a large vessel occlusion were included from a Dutch nationwide cohort (n=703) if CTP imaging was performed before EVT within 6 hours after stroke onset. Simulated cost and health effects during 5 and 10 years follow-up were compared between CTP based patient selection for EVT and providing EVT to all patients. Outcome measures were the net monetary benefit at a willingness-to-pay of €80 000 per quality-adjusted life year, incremental cost-effectiveness ratio), difference in costs from a healthcare payer perspective (ΔCosts) and quality-adjusted life years (ΔQALY) per 1000 patients for 1000 model iterations as outcomes. Results Compared with treating all patients, CTP-based selection for EVT at the optimised ischaemic core volume (ICV≥110 mL) or core-penumbra mismatch ratio (MMR≤1.4) thresholds resulted in losses of health (median ΔQALYs for ICV≥110 mL: -3.3 (IQR: -5.9 to -1.1), for MMR≤1.4: 0.0 (IQR: -1.3 to 0.0)) with median ΔCosts for ICV≥110 mL of -€348 966 (IQR: -€712 406 to -€51 158) and for MMR≤1.4 of €266 513 (IQR: €229 403 to €380 110)) per 1000 patients. Sensitivity analyses did not yield any scenarios for CTP-based selection of patients for EVT that were cost-effective for improving health, including patients aged ≥80 years Conclusion In EVT-eligible patients presenting within 6 hours after symptom onset, excluding patients based on CTP parameters was not cost-effective and could potentially harm patients.
AB - Background Although CT perfusion (CTP) is often incorporated in acute stroke workflows, it remains largely unclear what the associated costs and health implications are in the long run of CTP-based patient selection for endovascular treatment (EVT) in patients presenting within 6 hours after symptom onset with a large vessel occlusion. Methods Patients with a large vessel occlusion were included from a Dutch nationwide cohort (n=703) if CTP imaging was performed before EVT within 6 hours after stroke onset. Simulated cost and health effects during 5 and 10 years follow-up were compared between CTP based patient selection for EVT and providing EVT to all patients. Outcome measures were the net monetary benefit at a willingness-to-pay of €80 000 per quality-adjusted life year, incremental cost-effectiveness ratio), difference in costs from a healthcare payer perspective (ΔCosts) and quality-adjusted life years (ΔQALY) per 1000 patients for 1000 model iterations as outcomes. Results Compared with treating all patients, CTP-based selection for EVT at the optimised ischaemic core volume (ICV≥110 mL) or core-penumbra mismatch ratio (MMR≤1.4) thresholds resulted in losses of health (median ΔQALYs for ICV≥110 mL: -3.3 (IQR: -5.9 to -1.1), for MMR≤1.4: 0.0 (IQR: -1.3 to 0.0)) with median ΔCosts for ICV≥110 mL of -€348 966 (IQR: -€712 406 to -€51 158) and for MMR≤1.4 of €266 513 (IQR: €229 403 to €380 110)) per 1000 patients. Sensitivity analyses did not yield any scenarios for CTP-based selection of patients for EVT that were cost-effective for improving health, including patients aged ≥80 years Conclusion In EVT-eligible patients presenting within 6 hours after symptom onset, excluding patients based on CTP parameters was not cost-effective and could potentially harm patients.
KW - HEALTH ECONOMICS
KW - IMAGE ANALYSIS
KW - NEURORADIOLOGY
KW - STROKE
U2 - 10.1136/jnnp-2023-331862
DO - 10.1136/jnnp-2023-331862
M3 - Article
SN - 0022-3050
VL - 95
SP - 515
EP - 527
JO - Journal of Neurology Neurosurgery and Psychiatry
JF - Journal of Neurology Neurosurgery and Psychiatry
IS - 6
ER -